Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Gross Profit (2021 - 2025)

Oncology Institute (TOI) has disclosed Gross Profit for 5 consecutive years, with $225.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 165.79% year-over-year to $225.8 million, compared with a TTM value of $561.8 million through Sep 2025, up 57.2%, and an annual FY2024 reading of $392.1 million, up 21.15% over the prior year.
  • Gross Profit was $225.8 million for Q3 2025 at Oncology Institute, up from $68.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $225.8 million in Q3 2025 and bottomed at -$9.3 million in Q4 2021.
  • Average Gross Profit over 5 years is $74.0 million, with a median of $57.3 million recorded in 2025.
  • The sharpest move saw Gross Profit tumbled 91.65% in 2024, then surged 2229.36% in 2025.
  • Year by year, Gross Profit stood at -$9.3 million in 2021, then soared by 455.14% to $33.0 million in 2022, then soared by 430.18% to $175.2 million in 2023, then increased by 19.83% to $209.9 million in 2024, then rose by 7.57% to $225.8 million in 2025.
  • Business Quant data shows Gross Profit for TOI at $225.8 million in Q3 2025, $68.7 million in Q2 2025, and $57.3 million in Q1 2025.